(Repeats to fix formatting)
PARIS, Nov 24 (Reuters) - French biotech Vivalis VLS.PA and its British partner GlaxoSmithKline GSK.L have won U.S. clearance to begin testing for the first time on humans flu vaccines that were produced using Vivalis's technology.
Vivalis said in a statement on Wednesday that the terms of the milestone were not disclosed. Typically, biotech companies receive fees from partnership deals when a drug progresses in its development.
The Food and Drug Administration (FDA) accepted a so-called investigational new drug application that will allow GSK to test its influenza vaccine produced in Vivalis’s duck stem cell line EB66 technology on humans in an early stage Phase I trial. It is the first time that Vivalis’ technology, which is quicker, simpler and cleaner than developing vaccines in chicken eggs, has been put through regulatory screening.
Vivalis has said the flu vaccine could be the first EB66-based human vaccine to be marketed in 2015. [ID:nLDE65G1IT]
Vivalis shares closed at 7.28 euros on Tuesday. (Reporting by Caroline Jacobs; Editing by Jon Loades-Carter)
Our Standards: The Thomson Reuters Trust Principles.